Insmed Incorporated reiterated sales guidance for the full-year 2024. For the year, company expects sales guidance global ARIKAYCE revenues in the range of $340 million to $360 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
55.05 USD | -3.39% | +150.23% | +77.64% |
May. 31 | Stifel Adjusts Price Target on Insmed to $67 From $39, Maintains Buy Rating | MT |
May. 31 | Insmed Insider Sold Shares Worth $1,362,075, According to a Recent SEC Filing | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+77.64% | 8.87B | |
+11.91% | 118B | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B |
- Stock Market
- Equities
- INSM Stock
- News Insmed Incorporated
- Insmed Incorporated Reiterates Sales Guidance for the Full-Year 2024